The Applied Genetic Technologies Corporation is a publicly traded (NASDAQ:AGTC) biotechnology company that is part of the NASDAQ Biotechnology Index. It was founded in 1999 and has its headquarters in Alachua, Florida.
The company focuses on ophthalmologic genetic diseases. The company's technologies are aimed at products that might have the potential to treat achromatopsia, X-linked retinoschisis, X-linked retinitis pigmentosa, and age-related macular degeneration. The company has six products in various stages of development; as of 2016, none had yet been approved.